These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 1914843)
1. In vitro studies with Bay V 3522, a new oral cephalosporin. Thomson KS; Sanders CC; Sanders WE Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins. Locher R; Strässle A; Kayser FH Drugs Exp Clin Res; 1990; 16(10):515-25. PubMed ID: 2100734 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
4. Cefdinir: in vitro activity study and effect of human serum. García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142 [TBL] [Abstract][Full Text] [Related]
5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522. Chin NX; Gu JW; Neu HC Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis. Doern GV; Tubert TA Diagn Microbiol Infect Dis; 1990; 13(4):349-52. PubMed ID: 2127558 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Chin NX; Neu HC Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of BAY v 3522, a new oral cephalosporin. Fass RJ Antimicrob Agents Chemother; 1990 Sep; 34(9):1855-7. PubMed ID: 2126697 [TBL] [Abstract][Full Text] [Related]
10. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates. Jones RN; Barry AL Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients. Sultan T; Baltch AL; Smith RP; Ritz W Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638 [TBL] [Abstract][Full Text] [Related]
12. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Neu HC; Saha G; Chin NX Antimicrob Agents Chemother; 1989 Oct; 33(10):1795-800. PubMed ID: 2589845 [TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218. Johnson DM; Jones RN Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens. Ritchie DJ; Hopefl AW; Milligan TW; Byrne JE; Maddux MS Clin Ther; 1993; 15(1):107-13. PubMed ID: 8458040 [TBL] [Abstract][Full Text] [Related]
16. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir. Payne DJ; Amyes SG Drugs Exp Clin Res; 1992; 18(6):225-31. PubMed ID: 1478161 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Briggs BM; Jones RN; Erwin ME; Barrett MS; Johnson DM Diagn Microbiol Infect Dis; 1991; 14(5):425-34. PubMed ID: 1797457 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of cefcanel versus other oral cephalosporins. Chin NX; Gu JW; Neu HC Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):676-82. PubMed ID: 1748125 [TBL] [Abstract][Full Text] [Related]
19. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro. Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683 [TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Neu HC; Chin NX; Labthavikul P Antimicrob Agents Chemother; 1984 Aug; 26(2):174-80. PubMed ID: 6333207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]